Affiliations: [a]
Taipei City Hospital Yangming Branch, Taiwan, ROC | [b] Department of Logistics Management, National Kaohsiung University of Science and Technology,
Kaohsiung, Taiwan, ROC | [c]
Department of Healthcare Administration and Medical Informatics, Kaohsiung Medical University, Kaohsiung, Taiwan, ROC | [d]
Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, ROC | [e] SOE Technology Inc., Taipei, Taiwan, ROC
Correspondence:
[*]
Corresponding author. Yenming J. Chen, Department of Logistics Management, National Kaohsiung University of Science and Technology, Kaohsiung, Taiwan, ROC. E-mail: yjjchen@nkust.edu.tw and Wen-Hsien Ho, Department of Healthcare Administration and Medical Informatics, Kaohsiung Medical University, Kaohsiung, Taiwan, ROC. E-mail: whho@kmu.edu.tw.
Abstract: This study assesses the possible side effects of various doses of dapagliflozin. Dapagliflozin is a hypoglycemic agent that inhibits sodium-glucose co-transporter-2 (SGLT2) to remove excess glucose from the body through urination. Hence, dapagliflozin increases the risk for urinary tract infection (UTI) compared with other hypoglycemic agents. Clarifying the side effects of dapagliflozin at different doses and whether these effects are influenced by gender or other factors is significant. Through reviewing the literature on dapagliflozin treatment, we performed a meta-analysis of factors affecting UTI. We then determined the correlation of dapagliflozin treatment with UTI from the pooled data. Each dosing, gender group, or dapagliflozin added to other drugs for diabetes reported a percentage of contracting UTI. Basing on a reference number of pretreatment probability in UTI among patients with diabetes mellitus, we obtained the post-treatment probability in contracting the infection through the meta-analysis. We assessed the risk factors of UTI due to dapagliflozin administration on the basis of the results of odds ratio, regression analysis, and t-test. Considering the add-on-response relation, we recommend that the best add-on hypoglycemic agents to achieve low-risk UTI and control blood glucose are metformin or glimepiride. We also recommend that the best dosage of dapagliflozin is at 1 mg or 2.5 mg.
